<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019ff66a-f402-7714-90fc-defddacd2791,g:123ce587-fce1-4f40-8fcb-25380b786150-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhvn-20260930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7571-ad51-935f1db3a873" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019ff66a-f52f-755a-917f-a765c1461fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7571-ad51-935f1db3a873" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019ff66a-f52f-755a-917f-a765c1461fa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019ff66a-f52f-722c-8260-3810875b9104" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7571-ad51-935f1db3a873" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019ff66a-f52f-722c-8260-3810875b9104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ff66a-f52f-730c-8749-f1378a632ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7571-ad51-935f1db3a873" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ff66a-f52f-730c-8749-f1378a632ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019ff66a-f52f-70dd-ba6f-64b4b994382f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7571-ad51-935f1db3a873" xlink:to="loc_us-gaap_OtherAssetsCurrent_019ff66a-f52f-70dd-ba6f-64b4b994382f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019ff66a-f52f-74d5-8784-a2379a78f6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7811-a612-f74d0801ec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ff66a-f52f-74d5-8784-a2379a78f6eb" xlink:to="loc_us-gaap_AssetsCurrent_019ff66a-f52f-7811-a612-f74d0801ec2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019ff66a-f52f-7405-98d9-6e5aa2ec2c63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ff66a-f52f-74d5-8784-a2379a78f6eb" xlink:to="loc_us-gaap_Goodwill_019ff66a-f52f-7405-98d9-6e5aa2ec2c63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019ff66a-f52f-7dad-a6fd-54d33f7b7e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ff66a-f52f-74d5-8784-a2379a78f6eb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019ff66a-f52f-7dad-a6fd-54d33f7b7e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019ff66a-f52f-7337-96a0-099b69feb5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ff66a-f52f-74d5-8784-a2379a78f6eb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019ff66a-f52f-7337-96a0-099b69feb5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019ff66a-f52f-710b-a077-bfeb2d0246df" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019ff66a-f52f-74d5-8784-a2379a78f6eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019ff66a-f52f-710b-a077-bfeb2d0246df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019ff66a-f52f-79fa-9a4a-b85ac9283f03" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019ff66a-f52f-74df-b4b3-f75a9530c8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019ff66a-f52f-79fa-9a4a-b85ac9283f03" xlink:to="loc_us-gaap_AccountsPayableCurrent_019ff66a-f52f-74df-b4b3-f75a9530c8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f52f-71a5-aa30-4d636af4d456" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019ff66a-f52f-79fa-9a4a-b85ac9283f03" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f52f-71a5-aa30-4d636af4d456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ff66a-f52f-79e0-aad2-0ce7482da6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019ff66a-f52f-7d4e-97c4-3088c141ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ff66a-f52f-79e0-aad2-0ce7482da6e1" xlink:to="loc_us-gaap_PreferredStockValue_019ff66a-f52f-7d4e-97c4-3088c141ad18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ff66a-f52f-7171-963f-66e6ef46cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ff66a-f52f-79e0-aad2-0ce7482da6e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019ff66a-f52f-7171-963f-66e6ef46cf9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019ff66a-f52f-7ee0-8130-3de41c9643c2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ff66a-f52f-79e0-aad2-0ce7482da6e1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019ff66a-f52f-7ee0-8130-3de41c9643c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019ff66a-f52f-7385-b8c2-130900abc430" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ff66a-f52f-79e0-aad2-0ce7482da6e1" xlink:to="loc_us-gaap_CommonStockValue_019ff66a-f52f-7385-b8c2-130900abc430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ff66a-f52f-7c1a-8715-6f8e3f942409" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019ff66a-f52f-79e0-aad2-0ce7482da6e1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019ff66a-f52f-7c1a-8715-6f8e3f942409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ff66a-f52f-7a88-8bde-350b7d395a09" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019ff66a-f52f-7432-a973-44aa24b47fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ff66a-f52f-7a88-8bde-350b7d395a09" xlink:to="loc_us-gaap_Liabilities_019ff66a-f52f-7432-a973-44aa24b47fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019ff66a-f52f-7951-9122-8b55c0ade2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ff66a-f52f-7a88-8bde-350b7d395a09" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019ff66a-f52f-7951-9122-8b55c0ade2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019ff66a-f52f-7940-9099-63bd988d01b8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019ff66a-f52f-7a88-8bde-350b7d395a09" xlink:to="loc_us-gaap_StockholdersEquity_019ff66a-f52f-7940-9099-63bd988d01b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019ff66a-f52f-762d-8b47-72a7bacfb1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019ff66a-f52f-736d-a033-26a15e2f2a37" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019ff66a-f52f-762d-8b47-72a7bacfb1b0" xlink:to="loc_us-gaap_LiabilitiesCurrent_019ff66a-f52f-736d-a033-26a15e2f2a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019ff66a-f52f-7fdb-b0f3-08434009a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019ff66a-f52f-762d-8b47-72a7bacfb1b0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019ff66a-f52f-7fdb-b0f3-08434009a2ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019ff66a-f52f-70e4-88b8-3f6cc140b736" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019ff66a-f52f-762d-8b47-72a7bacfb1b0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019ff66a-f52f-70e4-88b8-3f6cc140b736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_019ff66a-f52f-7430-aa4a-885d4453a954" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019ff66a-f52f-762d-8b47-72a7bacfb1b0" xlink:to="loc_us-gaap_LongTermNotesPayable_019ff66a-f52f-7430-aa4a-885d4453a954" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhvn-20260930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ff66a-f52f-7abd-bdcd-5edc391e1b97" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-75bf-9a92-1534474ba135" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ff66a-f52f-7abd-bdcd-5edc391e1b97" xlink:to="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-75bf-9a92-1534474ba135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019ff66a-f52f-718f-8430-864f54e8717b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019ff66a-f52f-7abd-bdcd-5edc391e1b97" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019ff66a-f52f-718f-8430-864f54e8717b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-76a0-ab7b-423b9ae9d107" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019ff66a-f52f-7c30-b0f7-5e0c88c04e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-76a0-ab7b-423b9ae9d107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019ff66a-f52f-7c30-b0f7-5e0c88c04e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019ff66a-f52f-7330-9d48-68f6c147e790" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-76a0-ab7b-423b9ae9d107" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019ff66a-f52f-7330-9d48-68f6c147e790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019ff66a-f52f-758c-a975-b93671c04dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ff66a-f52f-755f-9de7-f27aed9163fa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019ff66a-f52f-758c-a975-b93671c04dbf" xlink:to="loc_us-gaap_OperatingIncomeLoss_019ff66a-f52f-755f-9de7-f27aed9163fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019ff66a-f52f-79fa-9ca4-7e7c72e1e1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019ff66a-f52f-758c-a975-b93671c04dbf" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019ff66a-f52f-79fa-9ca4-7e7c72e1e1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019ff66a-f52f-778f-838e-8a27b972011b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019ff66a-f52f-715e-8700-540a3b5b19f6" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019ff66a-f52f-778f-838e-8a27b972011b" xlink:to="loc_us-gaap_CostsAndExpenses_019ff66a-f52f-715e-8700-540a3b5b19f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019ff66a-f52f-7edb-8ecb-f1ebd6d6b772" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019ff66a-f52f-7c43-b493-b4249d7cc318" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019ff66a-f52f-7edb-8ecb-f1ebd6d6b772" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019ff66a-f52f-7c43-b493-b4249d7cc318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019ff66a-f52f-7d4b-a898-7533305eb5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019ff66a-f52f-7edb-8ecb-f1ebd6d6b772" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019ff66a-f52f-7d4b-a898-7533305eb5a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhvn-20260930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019ff66a-f52f-7151-aa38-1932c8ca4e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_ShareBasedCompensation_019ff66a-f52f-7151-aa38-1932c8ca4e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_019ff66a-f52f-7b03-b84f-37c0f04d4bea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_019ff66a-f52f-7b03-b84f-37c0f04d4bea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_019ff66a-f52f-7e66-b790-26e2c5f360e3" xlink:href="bhvn-20260930.xsd#bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_019ff66a-f52f-7e66-b790-26e2c5f360e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019ff66a-f52f-7491-9495-ba3ddfb8911e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019ff66a-f52f-7491-9495-ba3ddfb8911e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019ff66a-f52f-7369-84fc-d61927fba747" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019ff66a-f52f-7369-84fc-d61927fba747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ChangeInFairValueOfDerivativeLiabilities_019ff66a-f52f-7e2a-a2b3-15482ab353f5" xlink:href="bhvn-20260930.xsd#bhvn_ChangeInFairValueOfDerivativeLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_bhvn_ChangeInFairValueOfDerivativeLiabilities_019ff66a-f52f-7e2a-a2b3-15482ab353f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-7ba9-9247-9818b6fefb29" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_NetIncomeLoss_019ff66a-f52f-7ba9-9247-9818b6fefb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019ff66a-f52f-7127-9c33-e3a9c5c486e1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019ff66a-f52f-7127-9c33-e3a9c5c486e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ff66a-f52f-74e6-a353-3e4e8026309a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019ff66a-f52f-74e6-a353-3e4e8026309a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_FairValueAdjustmentOfNotesPayable_019ff66a-f52f-7f5c-8f0e-6cee8bd0df01" xlink:href="bhvn-20260930.xsd#bhvn_FairValueAdjustmentOfNotesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f52f-74f6-8214-5c7257504c44" xlink:to="loc_bhvn_FairValueAdjustmentOfNotesPayable_019ff66a-f52f-7f5c-8f0e-6cee8bd0df01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7112-a205-b86458fc995b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019ff66a-f530-7be2-ae5a-4f1fa93791e8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7112-a205-b86458fc995b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019ff66a-f530-7be2-ae5a-4f1fa93791e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ff66a-f530-75af-92dc-80b29b38c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7112-a205-b86458fc995b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019ff66a-f530-75af-92dc-80b29b38c09a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019ff66a-f530-79c8-8cc1-329bc67710de" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7112-a205-b86458fc995b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019ff66a-f530-79c8-8cc1-329bc67710de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019ff66a-f530-7e2a-a775-656b30e7a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7112-a205-b86458fc995b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019ff66a-f530-7e2a-a775-656b30e7a13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ff66a-f530-78fa-bb52-e48be08d25b0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f530-77db-ad67-e4fdde53db5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ff66a-f530-78fa-bb52-e48be08d25b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019ff66a-f530-77db-ad67-e4fdde53db5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7b0c-a955-4bca702f8212" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ff66a-f530-78fa-bb52-e48be08d25b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019ff66a-f530-7b0c-a955-4bca702f8212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f530-79f4-beea-729bb8238db8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ff66a-f530-78fa-bb52-e48be08d25b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f530-79f4-beea-729bb8238db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ff66a-f530-7665-9583-9e178eaa6a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019ff66a-f530-78fa-bb52-e48be08d25b0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ff66a-f530-7665-9583-9e178eaa6a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f52f-71c6-af39-6682b89449d8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_019ff66a-f52f-786a-90c7-affbd3ddcf82" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f52f-71c6-af39-6682b89449d8" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_019ff66a-f52f-786a-90c7-affbd3ddcf82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019ff66a-f52f-787b-a924-d24b5688aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f52f-71c6-af39-6682b89449d8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019ff66a-f52f-787b-a924-d24b5688aba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019ff66a-f530-7377-b12b-5ce73a7e99bc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f52f-71c6-af39-6682b89449d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019ff66a-f530-7377-b12b-5ce73a7e99bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019ff66a-f530-7640-84e0-41f6772cccfa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f52f-71c6-af39-6682b89449d8" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019ff66a-f530-7640-84e0-41f6772cccfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_01a13984-8010-7436-98b2-5926637db0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019ff66a-f52f-71c6-af39-6682b89449d8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_01a13984-8010-7436-98b2-5926637db0b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ff66a-f530-70ea-9f32-d56d675b7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ff66a-f530-707c-b5f3-1ad554bcc559" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ff66a-f530-70ea-9f32-d56d675b7ba7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019ff66a-f530-707c-b5f3-1ad554bcc559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_019ff66a-f530-742a-85ea-c80dc1d9b139" xlink:href="bhvn-20260930.xsd#bhvn_RestrictedCashIncludedInOtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ff66a-f530-70ea-9f32-d56d675b7ba7" xlink:to="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_019ff66a-f530-742a-85ea-c80dc1d9b139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019ff66a-f530-773d-9e4a-a78bc2181a61" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019ff66a-f530-70ea-9f32-d56d675b7ba7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019ff66a-f530-773d-9e4a-a78bc2181a61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019ff66a-f530-773f-b660-4ab996c6fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019ff66a-f530-7bb2-8ff7-afcdaa1673d2" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019ff66a-f530-773f-b660-4ab996c6fad4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019ff66a-f530-7bb2-8ff7-afcdaa1673d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019ff66a-f530-7343-b4c6-e15c3172bd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019ff66a-f530-773f-b660-4ab996c6fad4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019ff66a-f530-7343-b4c6-e15c3172bd4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019ff66a-f530-74d4-83f9-14b896367aca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019ff66a-f530-773f-b660-4ab996c6fad4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019ff66a-f530-74d4-83f9-14b896367aca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#MarketableSecuritiesNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_019ff66a-f5ca-7ea2-a9ec-68055367a3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_019ff66a-f5ca-74a0-b017-d3e2aadf2114" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_019ff66a-f5ca-7ea2-a9ec-68055367a3d5" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_019ff66a-f5ca-74a0-b017-d3e2aadf2114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_019ff66a-f5ca-7d9e-94d1-0f70bada033e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_019ff66a-f5ca-7ea2-a9ec-68055367a3d5" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_019ff66a-f5ca-7d9e-94d1-0f70bada033e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_019ff66a-f5ca-7c8c-b160-528977f5189a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_019ff66a-f5ca-7dbe-b8d5-b58fc84ce841" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_019ff66a-f5ca-7c8c-b160-528977f5189a" xlink:to="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_019ff66a-f5ca-7dbe-b8d5-b58fc84ce841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019ff66a-f5ca-72fb-ac2e-fc1330f1ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_019ff66a-f5ca-7c8c-b160-528977f5189a" xlink:to="loc_us-gaap_InterestIncomeOther_019ff66a-f5ca-72fb-ac2e-fc1330f1ea6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019ff66a-f5ca-7a3c-8afd-d1395b94253d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_019ff66a-f5ca-78e8-bb46-33a58ab4eed3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019ff66a-f5ca-7a3c-8afd-d1395b94253d" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_019ff66a-f5ca-78e8-bb46-33a58ab4eed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019ff66a-f5ca-7ddb-9942-4418ee0e920b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019ff66a-f5ca-7a3c-8afd-d1395b94253d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019ff66a-f5ca-7ddb-9942-4418ee0e920b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_019ff66a-f5ca-7ff7-922b-e51881be30c7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019ff66a-f5ca-7a3c-8afd-d1395b94253d" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_019ff66a-f5ca-7ff7-922b-e51881be30c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_OtherCurrentAssetsFairValueDisclosure_019ff66a-f5ca-7780-bb89-5fea035a8e6a" xlink:href="bhvn-20260930.xsd#bhvn_OtherCurrentAssetsFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019ff66a-f5ca-7a3c-8afd-d1395b94253d" xlink:to="loc_bhvn_OtherCurrentAssetsFairValueDisclosure_019ff66a-f5ca-7780-bb89-5fea035a8e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019ff66a-f5ca-7f59-a6ab-c9583761be5a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_019ff66a-f5ca-7cef-9904-86a7a9d605be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019ff66a-f5ca-7f59-a6ab-c9583761be5a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_019ff66a-f5ca-7cef-9904-86a7a9d605be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019ff66a-f5cb-7c22-aeb3-0e70ccbdbaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019ff66a-f5cb-7f06-b16b-43917ea96415" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019ff66a-f5cb-7c22-aeb3-0e70ccbdbaf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019ff66a-f5cb-7f06-b16b-43917ea96415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019ff66a-f5cb-7f7c-9da7-0c867677b6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019ff66a-f5cb-7c22-aeb3-0e70ccbdbaf0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019ff66a-f5cb-7f7c-9da7-0c867677b6a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#BalanceSheetComponentsOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019ff66a-f5cb-7490-8d47-8726c23ffe31" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019ff66a-f5cb-796e-be38-9f82cd1343bd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_019ff66a-f5cb-7490-8d47-8726c23ffe31" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019ff66a-f5cb-796e-be38-9f82cd1343bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_019ff66a-f5cb-78f3-84c2-e8c5fc79c182" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_019ff66a-f5cb-7490-8d47-8726c23ffe31" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_019ff66a-f5cb-78f3-84c2-e8c5fc79c182" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhvn-20260930.xsd#BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f5cb-78e2-9f83-74546b3b3631" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019ff66a-f5cb-7e69-944a-96cf7dd1cb68" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f5cb-78e2-9f83-74546b3b3631" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019ff66a-f5cb-7e69-944a-96cf7dd1cb68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedClinicalTrialCostsCurrent_019ff66a-f5cb-7be3-9cdd-f620b92c3df6" xlink:href="bhvn-20260930.xsd#bhvn_AccruedClinicalTrialCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f5cb-78e2-9f83-74546b3b3631" xlink:to="loc_bhvn_AccruedClinicalTrialCostsCurrent_019ff66a-f5cb-7be3-9cdd-f620b92c3df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019ff66a-f5cb-7380-b24c-e73ebb3e259e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f5cb-78e2-9f83-74546b3b3631" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019ff66a-f5cb-7380-b24c-e73ebb3e259e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedConsiderationTrueUpLiability_019ff66a-f5cb-7b3a-9165-31fab6af60cc" xlink:href="bhvn-20260930.xsd#bhvn_AccruedConsiderationTrueUpLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f5cb-78e2-9f83-74546b3b3631" xlink:to="loc_bhvn_AccruedConsiderationTrueUpLiability_019ff66a-f5cb-7b3a-9165-31fab6af60cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019ff66a-f5cb-76b8-9b7d-dc39bd0cc967" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019ff66a-f5cb-78e2-9f83-74546b3b3631" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019ff66a-f5cb-76b8-9b7d-dc39bd0cc967" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
